Adiponectin and end-stage renal disease

Markaki, Anastasia; Psylinakis, Emmanuel; Spyridaki, Aspasia

doi:10.14310/horm.2002.1698

Cited by 27 publications

(20 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed increased serum adiponectin level in CKD patients, that is in line with most up to date clinical studies on adiponectin alterations in kidney diseases [9]. It is known that adiponectin is associated with decreased cardiovascular risk but only in people with normal kidney function.…”

Section: Discussionsupporting

confidence: 91%

Increased adiponectin gene expression in adipose tissue may be related to an abnormal serum fatty acid profile in patients with chronic kidney disease

Korczyńska¹,

Czumaj²,

Chmielewski³

et al. 2020

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only.

show abstract

Section: Discussionsupporting

confidence: 91%

Increased adiponectin gene expression in adipose tissue may be related to an abnormal serum fatty acid profile in patients with chronic kidney disease

Korczyńska¹,

Czumaj²,

Chmielewski³

et al. 2020

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…However, in this study, high adiponectin level was associated with an increased risk of adverse renal outcomes. In view of the clearance of serum adiponectin via glomerular filtration, higher serum adiponectin may be observed in CKD patients due to impaired urinary excretion 24 . Moreover, adiponectin levels decrease after kidney transplantation, implying that the kidneys play an important role in the biodegradation or elimination of this protein 25 .…”

Section: Discussionmentioning

confidence: 99%

High serum adiponectin as a biomarker of renal dysfunction: Results from the KNOW-CKD study

Song

Choi

et al. 2020

Sci Rep

View full text Add to dashboard Cite

High serum adiponectin is noted in several conditions of chronic kidney disease (cKD) and is a predictor for end stage renal disease. However, the relationship between adiponectin level and renal disease progression is not well established. this study aimed to determine the relationship between serum adiponectin levels and CKD progression. This prospective longitudinal study included 2238 patients from the Korean cohort Study for outcomes in patients with chronic Kidney Disease. patients were divided into quartiles according to their serum adiponectin level. Composite renal outcome was defined as one or more of the following: initiation of dialysis or transplantation, a twofold increase in baseline serum creatinine levels, or a 50% decline in the estimated glomerular filtration rate (eGFR) during the follow-up period. A cox proportional hazard ratio model was applied to analyze the relationship between composite renal outcome and serum adiponectin levels. Serum adiponectin level was inversely associated with eGFR (p < 0.001) and positively correlated with urine albumin-creatinine ratio. The highest quartile of serum adiponectin was associated with an increased risk of adverse renal outomes (HR, 1.39; 95%CI, 1.05-1.84; p=0.021). On time-dependent receiver operating characteristic curve analysis, predictive ability of adiponectin for renal outcomes disappeared after adjusting for eGFR. therefore, serum adiponectin may be a biomarker of renal dysfunction rather than a true risk factor in cKD progression. Chronic kidney disease (CKD) is a major public burden, with rising global prevalence 1. There is an urgent need to identify factors that may predict and prevent CKD progression. Adiponectin is a peptide hormone secreted from adipocytes, with anti-inflammatory, anti-diabetic, and anti-atherogenic properties 2,3. Low serum levels of adiponectin have been associated with obesity, insulin resistance, coronary heart disease, and metabolic syndrome in the general population 4-6. Paradoxically, serum adiponectin levels are elevated in patients with CKD and end-stage renal disease (ESRD) 7. Moreover, high serum adiponectin levels were associated with increased mortality in patients with stage 3 or 4 CKD in the Modification of Diet in Renal Disease (MDRD) study 8. High serum adiponectin predicts all-cause mortality and ESRD in type 1 diabetics 9,10 and is associated with increased albuminuria in CKD patients 11. High adiponectin has been found to predict renal disease progression in men with CKD, but not in women 12. Adiponectin has also been markedly increased in patients with nephrotic syndrome 13 and essential hypertension 14. However, in a study, transgenic upregulation of adiponectin in CKD mice prevented renal injury 15. Hypoadiponectinemia is also independently associated with the presence of metabolic syndrome, which is a risk factor for CKD 16. In addition, most research regarding adiponectin has been conducted in relatively small populations with a limited number of patients with type 1 diabetes 9 or obesity 17. Th...

show abstract

“…Corroborating these findings, the HSF group presented higher levels of adiponectin associated with reduced GFR which confirms kidney disease. In opposition, the HSF group that received the compound showed reduction in the levels, which can be explained by the amelioration of glomerular filtration rate by γ Oz in these animals, since adiponectin is excreted via kidney glomerular filtration [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Gamma Oryzanol Treats Obesity‐Induced Kidney Injuries by Modulating the Adiponectin Receptor 2/PPAR‐α Axis

Francisqueti

Ferron

Hasimoto

et al. 2018

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

The kidney is an important organ in the maintenance of body homeostasis. Dietary compounds, reactive metabolites, obesity, and metabolic syndrome (MetS) can affect renal filtration and whole body homeostasis, increasing the risk of chronic kidney disease (CKD) development. Gamma oryzanol (γOz) is a compound with antioxidant and anti-inflammatory activity that has shown a positive action in the treatment of obesity and metabolic diseases. Aim. To evaluate the effect of γOz to recover renal function in obese animals by high sugar-fat diet by modulation of adiponectin receptor 2/PPAR-α axis Methods. Male Wistar rats were initially randomly divided into 2 experimental groups: control and high sugar-fat diet (HSF) for 20 weeks. When proteinuria was detected, HSF animals were allocated to receive γOz or maintain HSF for more than 10 weeks. The following were analyzed: nutritional and biochemical parameters, systolic blood pressure, and renal function. In the kidney, the following were evaluated: inflammation, oxidative stress, and protein expression by Western blot. Results. After 10 weeks of γOz treatment, γOz was effective to improve inflammation, increase antioxidant enzyme activities, increase the protein expression of adiponectin receptor 2 and PPAR-α, and recover renal function. Conclusion. These results permit us to confirm that γOz is able to modulate PPAR-α expression, inflammation, and oxidative stress pathways improving obesity-induced renal disease.

show abstract

Adiponectin and end-stage renal disease

Cited by 27 publications

References 105 publications

Increased adiponectin gene expression in adipose tissue may be related to an abnormal serum fatty acid profile in patients with chronic kidney disease

Increased adiponectin gene expression in adipose tissue may be related to an abnormal serum fatty acid profile in patients with chronic kidney disease

High serum adiponectin as a biomarker of renal dysfunction: Results from the KNOW-CKD study

Gamma Oryzanol Treats Obesity‐Induced Kidney Injuries by Modulating the Adiponectin Receptor 2/PPAR‐α Axis

Contact Info

Product

Resources

About